Skip to main content
. Author manuscript; available in PMC: 2017 Dec 21.
Published in final edited form as: Leukemia. 2016 May 20;30(8):1803–1804. doi: 10.1038/leu.2016.129

Figure 1.

Figure 1

Impact of ibrutinib therapy on BTK- and CXCR4-associated proteins in primary CLL cells. Primary CLL cells from three patients (Pt) were isolated fresh from peripheral blood samples before treatment (baseline, designated as 0 week), and 4 weeks after 420 mg daily oral doses of ibrutinib. Blood samples were collected in green-top tubes and CLL cells were isolated by Ficoll-Hypaque gradient. Cell pellets were prepared for two immunoblots. The first immunoblot was used for total BTK (BD Biosciences 611116), and phospho-(Abcam 74012) and total CXCR4 (Abcam 58176). GAPDH (Novus NB600-502) was blotted for loading control. The second immunoblot (below dashed line) was used to test phospho-(Cell Signaling 2054) and total PKC (Abnova H00005587-B01P), and total GRK6 (Cell Signaling 5878) and Pim-1 (Sigma SAB1404205). GAPDH (Novus NB600-502) served as a protein loading control.